Skip to main content

Advertisement

Table 1 Baseline Characteristics of the Study Population

From: Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel

  Prasugrel Clopidogrel  
Variable (n = 20) (n = 20) p-Value
Age, yrs 61.1 ± 11.0 66.1 ± 11.2 0.16
Male, n (%) 17 (85) 13 (65) 0.14
Body mass index, kg/m2 27.4 ± 3.6 26.3 ± 4.3 0.37
Current Smoker, n (%) 7 (35) 4 (20) 0.24
Hypertension, n (%) 13 (65) 17 (85) 0.14
Dyslipidemia, n (%) 15 (75) 11 (55) 0.19
Diabetes, n (%) 8 (40) 7 (35) 0.74
SDB (ODI 3%), n (%) 6 (30) 6 (30) 1.00
Previous MI, n (%) 0 (0) 0 (0) 1.0
Previous AP, n (%) 2 (10) 1 (5) 0.55
Previous PCI, n (%) 2 (10) 1 (5) 0.55
Previous CABG, n (%) 0 (0) 0 (0) 1.0
Previous stroke, n (%) 1 (5) 1 (5) 1.0
PAD, n (%) 0 (0) 0 (0) 1.0
Family History of CAD, n (%) 8 (40) 6 (30) 0.51
LVEF, % 69.9 ± 6.3 69.4 ± 6.2 0.74
eGFR, ml/min/1.73m2 65.8 ± 18.5 68.2 ± 17.2 0.68
Platelet counts, ×103/μL 21.0 ± 5.9 20.0 ± 4.2 0.54
Medications
 Aspirin, n (%) 20 (100) 20 (100) 1.00
 PPI, n (%) 15 (75) 11 (55) 0.19
 OAD, n (%) 8 (40) 4 (20) 0.17
 Insulin therapy, n (%) 0 (0) 1 (5) 0.31
 Statins, n (%) 15 (75) 11 (55) 0.19
 Nitrates, n (%) 6 (30) 3 (15) 0.26
 CCB, n (%) 9 (45) 10 (50) 0.75
 ACEIs/ ARBs, n (%) 11 (55) 11 (55) 1.00
 Beta blockers, n (%) 15 (75) 12 (60) 0.31
  1. Values are mean ± SD or n (%)
  2. ACEIs Angiotensin converting enzyme inhibitors, AP Angina pectoris, ARBs Angiotensin receptor blockers, CABG Coronary artery bypass surgery, CAD Coronary artery disease, CCB Calcium channel blockers, LVEF Left ventricular ejection fraction, MI Myocardial infarction, OAD Oral antidiabetic drug, PCI Percutaneous coronary intervention, PPI Proton pump inhibitor, SDB Sleep-disordered breathing